The U.S. Supreme Court has agreed to consider reinstating full access to the abortion drug mifepristone, once again entering the fraught territory of abortion litigation less than two years after its bombshell ruling in Dobbs.

In unexplained orders Wednesday morning, the U.S. Supreme Court granted petitions for review a Fifth Circuit opinion restricting distribution of the medication mifepristone, The petitions for review came from the U.S. Food and Drug Administration and Danco Laboratories, a company that manufactures the “abortion pill,” now the most common method of abortion in the country.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]